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Abstract  
 
Purpose: The use of sutureless clear corneal incisions (CCI) for 
phacoemulsification is an established surgical technique, but the dynamic 
morphology of the wound and poor construction can lead to an increased risk of 
post-operative endophthalmitis. Stromal hydration with balanced salt solution 
(BSS) can improve the self-sealing status. Intracameral cefuroxime has reduced 
endophthalmitis rates. This study investigates the safety profile of stromal 
hydration with cefuroxime, as sequestering antibiotic at the wound may 
potentially provide added protection against infection. 
 
Methods: MF-1 mice underwent bilateral CCI, followed by stromal hydration with 
either 5 µl of 10 mg/ml cefuroxime, cefuroxime-texas red conjugate (for detection 
using confocal microscopy), or BSS. Corneas were harvested from 1 hour to 12 
weeks post-operatively; gross morphology, histology and apoptotic cell-death 
levels were investigated to determine the safety profile. Bactericidal activity of 
cefuroxime was assayed using homogenised whole cornea following stromal 
hydration at 1 hr, 24 hrs and day 7 against gram-negative Escherichia coli.  
 
Results: Cefuroxime stromal hydration did not alter corneal morphology, with no 
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evidence of corneal scarring or vascularisation. Corneal histology and levels of 
apoptosis were minimal and comparable to the BSS groups up to 12 weeks. 
Confocal microscopy detected cefuroxime-texas red up to 1 week surrounding 
the corneal wound. Whole corneal tissue homogenates displayed bactericidal 
activity up to 24 hrs post operatively.   
 
Conclusions: Stromal hydration of CCI with cefuroxime is safe in mouse corneas. 
A reservoir of antibiotic at the wound can potentially act as a barrier of defence 
against infection following cataract and associated ocular surgery. 
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Introduction 
 
Cataract surgery is the most common operative procedure in the elderly 
population.1 Endophthalmitis is a potentially blinding complication of cataract 
surgery caused by severe intraocular inflammation. It usually presents within a 
few days following cataract surgery, with 80% of cases within six weeks. The 
majority of culture-proven cases of post-operative endophthalmitis are due to 
gram-positive bacteria, namely Staphylococcus epidermidis and other 
coagulase-negative staphylococci, which reside on the ocular surface and are 
presumed to enter the eye through the surgical incision.2 The use of clear 
corneal incisions (CCI) for cataract surgery has soared in popularity over the past 
20 years. In the 2003 survey of practice styles and preferences of the American 
Society of Cataract & Refractive Surgeons (ASCRS) members, CCI were used 
by 72% of respondents as their preferred cataract surgery technique.3 It has 
been suggested that there is an increased risk of post-operative endophthalmitis 
associated with the use of sutureless CCI.4-6 This is due to the dynamic 
morphology of the wound, which may remain apposed in a well-pressurized eye, 
however natural fluctuation in intraocular pressure (IOP) within the physiological 
range of 5-40 mmHg can result in shifting and gaping of the wound edge.7 This 
can lead to the ingression of ocular surface fluid including bacteria into the 
anterior chamber, with one retrospective cohort study showing that wound leak 
on day-1 post-op increased the risk of post-operative endophthalmitis by 44-
fold.8 The paracentesis wound has also been shown to leak using India ink, even 
in the absence of fluorescein leakage,8 hence, attention to the construction of all 
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CCIs is imperative. To improve the self-sealing status of corneal incisions, 
intrastromal hydration of the wound can be performed with balanced salt solution 
(BSS).9  
 
In 2007, the European Society of Cataract & Refractive Surgeons (ESCRS) 
Endophthalmitis Study Group reported that the use of intracameral cefuroxime at 
the end of surgery significantly reduced the occurrence of postoperative 
endophthalmitis.10 The Cochrane review on perioperative antibiotics for 
prevention of acute endophthalmitis after cataract surgery found the results of 
the ESCRS study, the only prospective and randomised multicentre clinical trial, 
to provide the best evidence for antibiotic prevention of endophthalmitis.1 In a 
recent survey investigating the adoption of intracameral antibiotic prophylaxis by 
193 ophthalmic surgeons affiliated with private and public hospitals and clinics 
across Europe, 74% reported they always or usually used intracameral 
antibiotics (of which 82% used cefuroxime) in their cataract procedures.11  
 
Cefuroxime is a bactericidal β-lactam second-generation cephalosporin. It acts 
by binding to specific penicillin-binding proteins (PBPs), which subsequently 
interferes with the peptidoglycan synthesis of the bacterial cell wall.12 Cell lysis 
ensues following activation of bacterial cell wall autolytic enzymes such as 
autolysins. Cefuroxime is effective against aerobic gram-positive microorganisms 
(Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus 
pyogenes); aerobic gram-negative microorganisms (Escherichia coli, 
Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, 
Haemophilus influenzae and Neisseria gonorrhoeae including beta-lactamase-
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producing strains); and spirochetes such as Borrelia burgdorferi. 
 
Safe perioperative measures that can be implemented as prophylaxis against 
intraocular microbial contamination may further reduce the rates of post-
operative endophthalmitis. In this study, we suggest stromal hydration of clear 
corneal incisions using cefuroxime may provide a safe and effective method of 
sequestering therapeutic levels of antibiotic at the wound site, with the potential 
of providing another barrier of defence against infection.  
 
Materials and methods  
 
Animals  
 
Six-week-old MF-1 albino mice (from Harlan UK) were used in this study. They 
were maintained in a 12/12-hour light–dark cycle with free access to water and 
food at the Imperial College London animal facility according to standard 
protocols and the guidelines of the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. The local institutional review board approved 
this study. 
 
Before performing surgical clear corneal incisions and stromal hydration, the 
mice were anaesthetised by intramuscular injection (0.01 ml/10 g body weight) of 
a mixture of 100 mg/ml ketamine hydrochloride (Narketan-10, Vétoquinol UK 
Ltd), 1 mg/ml medetomidine hydrochloride (Domitor®, Orion Pharma) and double 
distilled water at a ratio of 3:5:42, respectively. The anaesthesia was later 
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reversed by the intramuscular injection (0.01 ml/10 g of body weight) of 0.1 
mg/ml atipamezole hydrochloride (Antisedan®, Orion Pharma). At the end of the 
follow-up period (1 hr, 24 hr, and weeks 1, 6 and 12 post-operatively), the mice 
were euthanized by intra-peritoneal injection of an overdose (80-90 mg/kg body 
weight) of sodium pentobarbital (Euthatal, Merial Animal Health Ltd). The eyes 
were then enucleated and the corneas excised. Non-operated corneas were 
used as the negative control.  
 
Clear corneal incision and stromal hydration 
 
The cornea was lubricated with a drop of Hypromellose 0.3% w/v (Martindale 
Pharma®, chemical name hydroxypropyl methylcellulose C56H108O30) and excess 
fluid removed using a spear-shaped sponge (Harvard Apparatus). A 0.6 mm 
clear corneal incision was then placed in the temporal aspect of each cornea 
using an incisional micrometer diamond knife (DGH Technology Ltd). 
Intracorneal stromal hydration through the lips of the wound was performed using 
a 34-gauge Hamilton needle mounted onto polyethylene tubing (IntramedicTM) 
and a gas tight 50 µl Hamilton glass barrel. The right corneal stroma was 
hydrated with 5 µl of 1 mg/0.1 ml (or 10 mg/ml) cefuroxime solution. The left eye 
was hydrated with 5 µl balanced salt solution (BSS©, Alcon Laboratories) to 
serve as a control.  
 
Cefuroxime and Cefuroxime-Texas Red®-X conjugate 
 
Cefuroxime sodium powder (GlaxoSmithKline) was dissolved in balanced salt 
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solution (BSS©, Alcon Laboratories) to a concentration of 1 mg/0.1 ml (or final 
concentration 10 mg/ml). This was made up fresh for each application. To 
assess sequestration of cefuroxime at the site of the CCI following stromal 
hydration, confocal microscopy was used to monitor the presence of cefuroxime-
Texas Red®-X conjugate. To prepare the conjugate, 0.3 ml of 2 mg/ml stock 
solution of Texas Red®-X succinimidyl esters (Invitrogen Molecular Probes) 
dissolved in DMSO was agitated with 2.2 ml of cefuroxime (50 mg/ml stock) 
overnight at 4°C in the dark. This preparation was diluted with double distilled 
water to a concentration of 10 mg/ml cefuroxime-Texas Red®-X and 5 µl was 
used to stromally hydrate the cornea; and 5 µl of 10 mg/ml Texas Red®-X alone 
was also injected into the corneal stroma as a control. Stacked images of the 
cornea were taken using the Leica SP5 inverted confocal microscope at 1 hr, 24 
hr and day 7. Total fluorescence intensity was measured (using Leica LAS AF 
Lite software) from each dissected cornea, n=3 at each aforementioned time 
point, providing a mean ± SEM fluorescence intensity per cornea for each 
treatment group. 
 
Bactericidal assay 
 
To determine the bactericidal activity of cefuroxime, harvested corneas at 1 hr, 
24 hr and day 7 post-stromal hydration were homogenised by sonication (3 x 15 
sec, XL-2000 Qsonica LLC) and the whole tissue homogenate was added to 50 
µl gram-negative bacteria Escherichia coli DH5α cells incubated with 5 ml Luria-
Bertani (LB) medium overnight at 37°C (n=3 corneas per time point). BSS-
hydrated corneas at corresponding time points were used as the negative 
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control, alongside untreated corneas (n=3). Direct inoculation of 5 µl of 10 mg/ml 
cefuroxime was used as a positive control. Following this 10 µl of each culture 
was plated on agar plates overnight at 37°C to assess levels of bactericidal 
activity. The number of colony forming units (CFU) per ml was calculated by 
counting each colony on 3 agar plates per condition, using a Molecular Imager 
(Gel-Doc XR; Bio-Rad Laboratories, Munich, Germany) and determining the 
mean colony count per ml plated, divided by the total dilution factor.  
 
Corneal histology and morphological studies 
 
Freshly excised corneas were fixed in 4% paraformaldehyde (PFA) for 4-6 hours 
at room temperature, then washed three times in PBS, dehydrated through a 
graded ethanol series (50, 70, 90% and three times in 100%), and finally 
embedded in paraffin wax. Microtome sections of 5 µm were cut, mounted on 
Superfrost Plus slides and stained with H&E.  
 
Corneal morphology and histology at various time points between 5 min and 12 
weeks were taken using a Nikon 5100 mounted on a Stemi 2000 C 7:1 zoom 
stereomicroscope. The central corneal thickness was measured from the 
histological sections using ImageJ, and mean CCT ± SEM (n=3 at each time 
point per treatment group) was calculated.  
 
TUNEL assay  
 
Excised corneas with cefuroxime and BSS stromal hydration were fixed in 4% 
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PFA and embedded in wax as described above at 1 hr, and weeks 1, 6 and 12 
post-operatively (n=3 at each time point per treatment group). Corneal sections 
were dewaxed by washing twice in histoclear (National Diagnostics), followed by 
two washes in 100% ethanol and once in 70% ethanol, before rinsing in 
deionized H2O. Sections were digested with proteinase K (10 mg/ml) for 15 min. 
Following the manufacturer’s instructions, the ApopTag® Peroxidase In Situ 
Apoptosis Detection Kit (Millipore) was used to detect levels of apoptotic cell 
death to determine the safety profile of the stromal hydration. 
 
Statistical Analysis 
 
All results are expressed as mean ± SEM, unless specified. As sample sizes are 
small, non-parametric tests were used. Differences between control non-
operated, BSS and cefuroxime-hydrated groups were assessed by pair-wise 
comparisons using the Mann-Whitney test or the Kruskal–Wallis analysis of 
variance if more than 2 groups were investigated, followed by Dunn’s multiple 
comparison test where appropriate, unless otherwise stated. A p-value of <0.01 
was considered statistically significant.  
 
Results: 
 
Stromal hydration of CCI with a 10 mg/ml concentration of cefuroxime did not 
adversely affect the cornea using an in vivo mouse model. The right and left eyes 
were stromally hydrated with 5 µl of 10 mg/ml cefuroxime and 5 µl of BSS, 
respectively. This volume of solution was chosen for intrastromal hydration as it 
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maximally hydrated the wound edges. Corneal morphology was comparable in 
both cefuroxime and BSS hydration groups at each time point from 1 hr to 6 
weeks (Fig 1A). By week 6 there was no gross morphological difference in 
appearance between operated and non-operated eyes. There was no evidence 
of corneal scarring or vascularisation up to 12 weeks post-operatively.  
 
Levels of apoptosis were assayed using TUNEL staining in both BSS and 
cefuroxime stromal hydration groups up to 12 weeks post-operatively. From day 
1 through to week 12 there was minimal evidence of cell death, and each cornea 
was comparable in both groups to a non-operated eye (Fig 1C).  
 
Corneal histology showed an increase in corneal thickness at 1 hr post-stromal 
hydration in both the BSS (mean 121.3 ± 2.6 µm) and cefuroxime (mean 121.0 ± 
1.6 µm) groups. Each group had comparable central corneal thickness (CCT) at 
each time point investigated (Fig 2), with no statistical difference (p>0.95): at one 
week post-operatively the mean CCT was 98.0 ± 1.4 µm in the BSS and 96.3 ± 
1.2 µm in the cefuroxime group; at 6 weeks post-operatively the mean CCT was 
93.7 ± 2.6 µm in the BSS and 92.0 ± 2.1 µm in the cefuroxime group; and at 12 
weeks the mean CCT was 87.3 ± 2.1 µm in the BSS and 88.3 ± 1.7 µm in the 
cefuroxime group similar in thickness to an untreated cornea, mean CCT 87.7 ± 
1.69 µm (no statistical difference, p>0.98).  
 
Cefuroxime-texas red conjugate and texas red alone was detected by confocal 
microscopy up to 1 week surrounding the corneal wound (Fig 3). Cumulative 
levels of fluorescence were measured from stacked images of each dissected 
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cornea stromally hydrated with cefuroxime-texas red (mean 42.5 x 105 ± 4.4 x 
104 fluorescence intensity/cornea) and texas red alone (mean 35.1 x 105 ± 4.0 x 
104 fluorescence intensity/cornea) at 1 hour post-operatively. This dropped by 
42.1% by day 1 post-operative in the cefuroxime-texas red group (mean 17.9 x 
105 ± 5.2 x 104 fluorescence intensity/cornea) and 42.7% in the texas red group 
(mean 15.0 x 105 ± 8.0 x 103 fluorescence intensity/cornea). At one week post-
operatively, in the cefuroxime-texas red group (mean 4.1 x 105 ± 1.6 x 104 
fluorescence intensity/cornea) less than 10% fluorescence intensity was detected 
compared to the 1 hr post-operative time point. This was similar in the texas red 
group (mean 3.6 x 105 ± 8.0 x 103 fluorescence intensity/cornea). No 
fluorescence was seen in the BSS hydrated corneas, which were used as the 
negative control. 
 
Microbiological tests to assess the bactericidal activity of cefuroxime in the 
stromally hydrated cornea showed a significant efficacy at 1 hr post procedure 
(2.1 x 106 ± 4.8 x 106 CFU/ml) compared to the BSS hydrated corneas at the 
same time point  (7.6 x 108 ± 3.2 x 107 CFU/ml) and non-operated cornea 
controls (7.7 x 108 ± 1.3 x 107 CFU/ml), p<0.01 (Fig 4). Although less than at 1 
hr, a significant degree of bactericidal activity was still seen at 24 hrs (2.4 x 108 ± 
2.7 x 107 CFU/ml) compared to the BSS hydrated corneas (7.5 x 108 ± 4.1 x 107 
CFU/ml) and negative control group, p<0.01. By day 7 there was no difference in 
cefuroxime hydrated corneas (7.4 x 108 ± 3.9 x 107 CFU/ml) compared to the 
BSS hydrated corneas (7.2 x 108 ± 6.6 x 107 CFU/ml) and non-operated cornea 
controls, p<0.95. When 5 µl of 10 mg/ml cefuroxime was added directly to the 
Escherichia coli DH5α cells, no growth was seen in the agar plates, suggesting 
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that this dose is bactericidal and optimum for administration into the eye (Fig 4).  
 
Discussion: 
 
Stromal hydration of CCI with 10 mg/ml cefuroxime appears safe in mouse 
corneas with demonstrable levels up to seven days post-operatively. This is 
consistent with a recent study which found that stromal hydration is detectable 
for at least one week in patients undergoing cataract surgery performed through 
CCI confirmed by 3-D corneal and anterior segment OCT. 13 Fine et al. used a 
Zeiss Visante anterior segment OCT to detect stromal swelling at 24 hours post-
cataract surgery but did not examine any later timepoints.14 A reservoir of 
antibiotic at the wound could act as a barrier of defence against infection, with 
the potential to reduce the risk of post-operative endophthalmitis following 
cataract and associated ocular surgery.  
 
Pharmacokinetic studies have shown that cefuroxime is excreted unchanged in 
the urine and has a half-life of 1-2 hours.15 A non-randomized observer-masked 
trial was conducted to investigate the safety and kinetics of prophylactic 
intracameral cefuroxime in patients who underwent uneventful 
phacoemulsification.16 Patients received a dose of 1 mg cefuroxime in 0.1 ml 
saline 0.9% into the anterior chamber at the end of surgery. One hour later, 
following aqueous sampling, a four-fold reduction in the levels of cefuroxime was 
detected from 2.74 mg/ml to 0.75 mg/ml. No further time points were measured 
and as there were no reports of aqueous turnover following cataract surgery, the 
true elimination rate could not be fully ascertained. From our study, the detection 
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of cefuroxime-texas red conjugate and corresponding bactericidal activity up to 
24 hrs, suggests adequate concentrations of cefuroxime were present in the 
cornea following surgery. Bacterial colonies were detected at both time points, 
compared to the direct administration of cefuroxime to the gram-negative 
bacteria Escherichia coli, but this is likely due to the dilution effect caused by 
using the whole cornea tissue homogenate. Nonetheless, presence of low levels 
of antibiotic had some inhibitory action on the growth of bacteria, and in practice, 
if concentrated around the wound edges will have a more potent protective 
effect. The main limitation of this study is the lack of serial drug level monitoring 
in the stroma, anterior chamber and tears. Further studies are warranted to 
measure the release of cefuroxime from the stroma to the aqueous humour and 
into the tears over time in order to determine the true elimination rate from the 
cornea, and whether its minimum inhibitory concentration (MIC) levels could be 
achieved for Staphylococcus epidermidis and other relevant bacteria associated 
with endophthalmitis.  
 
A recent study investigated the penetration of bevacizumab administered to 
BALB/c mouse eyes topically with a denuded corneal epithelium or via 
subconjunctival injection with an intact cornea.17 At 24 hours post administration 
there was evidence of widespread intracorneal diffusion with even stromal 
distribution throughout the whole cornea using both methods. Bevacizumab 
remained present in the central cornea for up to 14 days, declining at 21 days 
from the periphery. Due to its large molecular weight, 149 kDa, it was 
hypothesized that bevacizumab was removed by diffusion from the corneal 
periphery in a centripetal pattern slowly over weeks. In contrast, cefuroxime is a 
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small molecule, formula C16H16N4O8S, with a molecular mass of 424.386 Da, but 
this compound may act in a similar manner reducing in levels through diffusion 
secondary to its high concentration gradient in the stroma over time. Stromal 
hydration with cefuroxime would allow a known concentration of drug to be 
delivered to the cornea, which could act as a slow release mechanism at the 
wound site and into the anterior chamber. In theory, stromal hydration may be 
useful for patients where compliance may be an issue, as a bolus may cover the 
patient over the first few days up to one week post-operatively.  
 
There has been a reluctance to adopt the use of intracameral antibiotics, namely 
cefuroxime (0.1 mL of 10.0 mg/mL solution), over the past few years despite its 
result in a 5-fold reduction in the incidence of postoperative endophthalmitis. 
Fifty-five percent of surgeons surveyed in the United Kingdom in 2008 reported 
using intracameral cefuroxime, as compared with 10% in 2005.18 The 
unwillingness was mainly due to the concern of unintended dilution errors, 
endothelial toxicity and possible bacterial contamination. Previously, there were 
no ready-to-use ocular formulations of cefuroxime available, hence the 10 mg/ml 
solution was prepared in hospital pharmacies and stored at 4°C for a limited time 
or reconstituted by the surgeon in the operating room, which risked mistakes 
during the dilution. A series of 6 cases was published by Delyfer et al. 2011 
documenting the inadvertent administration of high dose (100 mg/ml) 
intracameral cefuroxime at the end of uneventful cataract surgery, secondary to 
misunderstanding of the dilution protocol.19 Each case resulted in moderate 
anterior inflammation and fibrin formation consistent with a mild form of toxic 
anterior segment syndrome or toxic endophthalmitis, which had resolved by day 
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5. All patients developed extensive macular oedema with an associated serous 
retinal detachment on day one post-operatively, which significantly improved in 
the first week. At six weeks CCT, endothelial cell density and macular anatomy 
had returned to normal in all patients consistent with those observed after 
uneventful phacoemulsification. Two-thirds of the surgeons not using 
intracameral cefuroxime stated they would adopt this step if a commercial 
preparation were available.18 A one-step reconstitution of cefuroxime 
(Aprokam®) is now available and this may encourage the use of intracameral 
cefuroxime and its further application in stromal hydration of the cornea.20 
However, a pre-filled single-use syringe containing 10 mg/ml cefuroxime would 
be ideal to eliminate any preparation and dosage errors. 
 
Our experiments show that there were minimal levels of cell death in the 
cefuroxime and BSS stromal hydration groups, both comparable to non-operated 
eyes. There have been many studies assessing the corneal endothelial changes 
after intracameral cefuroxime following cataract surgery. In a recent study 
endothelial cell density (ECD), coefficient of variation (CoV), and hexagonality 
were evaluated at baseline and 1 week, 1 month, and 3 months following 
intracameral cefuroxime (1 mg/0.1 ml) or vancomycin (1 mg/0.1 ml) after cataract 
surgery.21 The ECD was significantly reduced at 1 week post-surgery, after which 
it stabilized but overall it decreased by a mean of 12.1% at 3 months. There was 
no significant difference in the CoV or hexagonality preoperatively and at 
3 months postoperatively. 
 
There has been little advance in perioperative techniques for the prevention of 
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acute endophthalmitis over recent years. Prior to the 2007 ESCRS 
Endophthalmitis Study, which demonstrated the efficacy of using intracameral 
antibiotics for reducing endophthalmitis, only preoperative disinfection by 
povidone–iodine could reach the level II rating of scientific evidence.1, 22 Other 
reported prophylactic interventions, such as antibiotic-containing irrigating 
solutions, the use of intraoperative heparin and postoperative subconjunctival 
antibiotic injection received the lowest clinical recommendation based on weak 
evidence justifying their use.22 This preclinical study shows proof-of-concept for 
developing a new perioperative prophylactic intervention, which uses the same 
concentration of intracameral cefuroxime for stromal hydration of the surgical 
wounds. Anectodotally, this technique is in use by some cataract surgeons, 
however, the method has not been previously published in the literature. There is 
contention about the transferability of mouse corneal data to humans, but this 
study does confirm the safety of cefuroxime intrastromal hydration in murine 
models. Clinical trials would be required to assess the safety in patients with a 
view to evaluating this procedure using large patient groups to compare rates of 
post-operative endophthalmitis following cataract surgery.  
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Legends 
 
Figure 1. Morphology, histology and cell death assay comparing stromal 
hydration of a clear corneal incision with cefuroxime (CEF 10 mg/ml) or BSS in 
the mouse eye post-operatively. (A) Morphology of a non-operated mouse eye 
followed by images of a CEF hydrated cornea at 1 hr, day 1 and week 6 post-
operatively. Normal morphology can be seen at week 6, comparable to the BSS 
hydrated cornea shown at the end of the panel. No evidence of any corneal 
vascularisation or scarring. (B) Histology of the central cornea of an non-
operated mouse eye followed by comparable sections of CEF and BSS hydration 
groups at day 1 (maximum stromal hydration seen), and week 1, 6 and 12 post-
operatively. (C) Cell death assay on an non-operated mouse central corneal 
section was comparable to CEF and BSS hydration groups at all time points up 
to 12 weeks post-operatively with minimal to no cell death noted.  
 
Figure 2. Graphical representation showing the mean ± SD reduction in central 
corneal thickness (CCT in µm) following stromal hydration with cefuroxime (CEF, 
10 mg/ml) or BSS over time post-operatively from 1 hr up to 12 weeks (n = 3 per 
time point per group; WT, control non-operated eye). 
 
 
Figure 3. Fluorescence levels of cefuroxime-texas red conjugate following 
stromal hydration of the corneal wound. Stacked confocal fluorescent merged 
with bright field images of the cornea hydrated with cefuroxime-texas red 
conjugate (CEF-TR), texas red alone (TR) and BSS at 1 hr, 24 hrs and day 7 
post-operatively. Corresponding graph showing the mean fluorescence intensity 
x 105 per whole cornea ± SEM (n = 3 per time point per group) of CEF-TR and 
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TR. 
 
Figure 4. Graph to show the levels of bacteria (colony forming units [CFU]/ml) 
following inoculation with cefuroxime-stromally hydrated corneas (CEF) 
compared to BSS-hydrated corneas (BSS) at 1 hr, 24 hrs and day 7 post-
operatively. Negative control (-) was non-operated cornea and the positive 
control (+) was 5 µl of 10mg/ml cefuroxime. 
 
 
